At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

Ocugen (NasdaqCM:OCGN) just gave investors something to talk about by announcing a new licensing agreement that hands Kwangdong Pharmaceutical the exclusive rights to commercialize its gene therapy ...

Sangamo Therapeutics hasn’t convinced a pharma company to buy its experimental gene therapy for Fabry disease after two years ...

The White House is clamping down on pharma’s ability to buy new molecules from Chinese biotechs; Sanofi, Merck and others ...

A genome-editing technique known as prime editing holds potential for treating many diseases by transforming faulty genes into functional ones. However, the process carries a small chance of inserting ...

In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...

This week marks the 30th anniversary of Jeans for Genes, one of the UK’s most recognised fundraising campaigns, which has ...

Also, there’s still no easy way to test AI designs of larger genomes. While some viruses can ‘boot up’ just from a DNA strand ...

Since she was a newborn, Ruby Benevedes has shown great strength despite living with an advanced form of sickle cell disease.

New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation ...

CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene ...

Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable ...